The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Spruce Biosciences has put out new shoots, snapping up rights to a former BioMarin rare disease candidate and outlining plans ...

The South San Francisco biotech has acquired rights to tralesinidase alfa, an enzyme replacement therapy (ERT) for the ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...

Spruce is racing financial and regulatory time in taking over development of TA-ERT from now-shuttered Allievex Corp., which originally licensed the program from San Rafael-based BioMarin (Nasdaq ...

From Washington to Wall Street, it's a crazy time for biotech. But as Ultragenyx Pharmaceutical Inc. celebrates its 15th ...

Wall Street expects a year-over-year increase in earnings on higher revenues when BioMarin Pharmaceutical (BMRN) reports results for the quarter ended March 2025. While this widely-known consensus ...

Q1 2023 Earnings Call Transcript April 15, 2025 Spruce Biosciences, Inc. misses on earnings expectations. Reported EPS is $-0 ...

Sequentify is offering research grants to accelerate high-impact genomic studies through its uniquely fast, easy-to-use, and scalable targeted library preparation technology. Designed to enable the ...

The University of Glasgow's Living Laboratory for Precision Medicine and myDNA, a leader in precision health, have announced a new partnership to generate evidence supporting the adoption of ...

Spruce Biosciences (SPRB) announced the company’s new corporate strategy and acquisition of tralesinidase alfa enzyme replacement therapy for ...